Sequencing Radium-223 and Lutetium-177 PSMA Therapy in mCRPC Management: Insights from the RaLu Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxB7-H4-Targeting Antibody-Drug Conjugate, LNCB74, Gets Green Light for Clinical Trials for Solid Tumors
/0 Comments/in Clinical Trial, Phase 1/by MaxOP-3136: New Drug Receives FDA Clearance to Begin Clinical Trials
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxA New Dawn for Disease Treatment: Combining mRNA and RNAi Therapies
/0 Comments/in CRISPR, Preclinical Research/by MaxNewsletter 4
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the fourth newsletter from the site. In the next days I will be reporting some (hopefully) good news from an immune oncology symposium, fingers crossed! Some of the subscribers suggested me to reactivate the donations button, do you […]
Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/0 Comments/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxMapping the Gut: A New Atlas Illuminates the Path to Understanding and Treating Cancer (and other diseases)
/0 Comments/in Not PCa related, Preclinical Research/by MaxPreclinical: A More Efficient and Selective Path to Anti-Cancer Drugs
/0 Comments/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- MDNA113 a Potentially Groundbreaking Immune Therapy for Solid Tumors Including mCRPC June 30, 2025
- Newsletter 26/2025 June 29, 2025
- AlphaGenome: Another Incredible AI Tool for Biology June 27, 2025
- Phase 1 Trial of 225Ac-ETN029 for Neuroendocrine Prostate Cancer June 26, 2025